The introduction of antivascular endothelial growth factor agents such as ranibizumab and
aflibercept has revolutionized the management of neovascular age-related macular …

Pigment epithelial detachment (PED), the anatomical separation of the retinal pigment
epithelium from the Bruch membrane, is common in many chorioretinal diseases, including …

Purpose To investigate short-term treatment outcomes of intravitreal brolucizumab (IVBr) for
treatment-naïve neovascular age-related macular degeneration (AMD) in a Japanese …

Purpose To analyze the effect of baseline presence and height of pigment epithelial
detachments (PEDs) on visual and anatomic outcomes at 24 months in patients with …

Background Despite the good outcomes achieved with intravitreal angiogenic therapy, a
subset of neovascular age-related macular degeneration (AMD) patients experience …

Purpose: To evaluate the response to aflibercept therapy for Type 1 and Type 3
neovascularization in pigment epithelial detachments associated with treatment-naive …

Purpose The purpose of this study was to investigate the structural variations of the
hyporeflective pocket of fluid (prechoroidal cleft) located between Bruch's membrane and …

Purpose To report the efficacy and safety of brolucizumab in the treatment of refractory
serous pigment epithelial detachment (PED) secondary to polypoidal choroidal …

Purpose: To analyze the efficacy of aflibercept switch treatment for regression of pigment
epithelial detachment (PED) in patients previously treated with ranibizumab. Methods …

Background To study the clinical outcomes of pigment epithelial detachment (PED)
associated with neovascular age-related macular degeneration (nAMD) in patients switched …